LXY1-CB-TE2A

LXY1-CB-TE2A is a peptide-based radiopharmaceutical conjugate designed for the targeting and imaging of glioblastoma. It consists of the LXY1 peptide, which specifically binds to the **integrin alpha-3/beta-1** (α3β1) receptor, conjugated to the cross-bridged macrocyclic chelator **CB-TE2A** (1,4,8,11-tetraazacyclotetradecane-1,8-diacetic acid). When complexed with copper-64 (64Cu), the conjugate serves as a positron emission tomography (PET) imaging agent. Developed at the University of California, Davis, LXY1-CB-TE2A has demonstrated the ability to efficiently target both orthotopic and subcutaneous glioblastoma in xenograft mouse models. While it shows high tumor accumulation, it also exhibits significant uptake in the liver and kidneys, suggesting its primary utility may be in diagnostic imaging rather than radiotherapy.

Other names

64Cu-LXY1-CB-TE2A